Bay Street News, January, 2019

Primary endpoint (safety and tolerability) met, with clinical benefit observed in 7 of 10 patients Proof-of-Concept established in agitated patients […]

Suvodirsen (WVE-210201) Phase 2/3 trial chosen in inaugural round of pilot program FDA pilot program is a 21st Century Cures […]

ATLANTA, Jan. 03, 2019 (GLOBE NEWSWIRE) — PRGX Global, Inc. (Nasdaq: PRGX), a global leader in Recovery Audit and Spend […]

NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics […]

JACKSONVILLE, Fla., Jan. 03, 2019 (GLOBE NEWSWIRE) — Stein Mart, Inc. (NASDAQ: SMRT) announced today that its chief executive officer, […]

SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security […]

CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) — Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on […]

TEMPLE CITY, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) — Fulgent Genetics (NASDAQ: FLGT) and the Precision Genomics Laboratory (PGL), in […]

RP1: U.S. Enrollment Opened for Phase 1/2 Clinical Trial in Combination with Nivolumab in Patients with Solid Tumors RP1: Randomized […]

HOLLYWOOD, Fla., Jan. 03, 2019 (GLOBE NEWSWIRE) — NV5 Global, Inc. (Nasdaq: NVEE) (“NV5” or the “Company”), a professional engineering […]